H3N2FLU.US

Novavax, Inc. (Nasdaq: NVAX ) announced today new data from a clinical study that began in May of 2009 among healthy adults 18 to 49 years of age with Novavax’s trivalent seasonal influenza Virus-like Particle (VLP) vaccine.

Continued here:
Novavax Reports Additional Positive Data From Its Trivalent Seasonal Influenza (VLP) Vaccine Clinical Study In Healthy … (BioresearchOnline)

Novavax, Inc. (Nasdaq: NVAX ) announced today new data from a clinical study that began in May of 2009 among healthy adults 18 to 49 years of age with Novavax’s trivalent seasonal influenza Virus-like Particle (VLP) vaccine.

See original here:
NOVAVAX Reports Additional Positive Data From Its Trivalent Seasonal Influenza (VLP) Vaccine Clinical Study In Healthy … (PharmaceuticalOnline)

ROCKVILLE, Md., Feb. 8 /PRNewswire-FirstCall/ — Novavax, Inc. (Nasdaq: NVAX) announced today new data from a clinical study that began in May of 2009 among healthy adults 18 to 49 years of age with Novavax’s trivalent seasonal influenza Virus-like Particle (VLP) vaccine.

Read the rest here:
NOVAVAX Reports Additional Positive Data from Its Trivalent Seasonal Influenza (VLP) Vaccine Clinical Study in Healthy … (redOrbit)

Novavax, Inc. (Nasdaq: NVAX) has begun a Phase IIa clinical study of its trivalent seasonal influenza VLP vaccine candidate in healthy adults 60 years of age or older.

Read more here:
Novavax Begins Phase IIa Study Of Seasonal Influenza Vaccine In Older Adults (Medical News Today)

Novavax, Inc. has begun a Phase IIa clinical study of its trivalent seasonal influenza VLP vaccine candidate in healthy adults 60 years of age or older.

View original post here:
Novavax Begins Phase IIa Study of Seasonal Influenza Vaccine in Older Adults (PR Newswire via Yahoo! Finance)

Novavax, Inc. a clinical-stage vaccine company, announced today that the Company made a poster presentation on the “Safety and Immunogenicity of a Recombinant Trivalent Seasonal Influenza Virus-like Particle Vaccine in Healthy Adults” on Saturday, October 31, 2009 at the 47 Annual Meeting of the Infectious Diseases Society of America .

Originally posted here:
Novavax Reports Positive Data for its Trivalent Seasonal Influenza (VLP) Vaccine Candidate in a Second Phase II Study (PR Newswire via Yahoo! Finance)

In the 2007–2008 season, the inactivated vaccine was efficacious in preventing laboratory-confirmed symptomatic influenza A (predominately H3N2 ) in healthy adults. The live attenuated vaccine also prevented influenza illnesses but was …

Original post:
A TIME'S MEMORY: Comparative Efficacy of Inactivated and Live …